• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS).

作者信息

Rossi Alexander J, Verbus Emily A, Horst Kathleen, De Martini Wendy, Allison Kimberly, Hernandez Jonathan M, Wapnir Irene L

机构信息

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA, USA.

出版信息

Ann Surg Oncol. 2022 Mar;29(3):1528-1529. doi: 10.1245/s10434-021-10552-7. Epub 2021 Sep 2.

DOI:10.1245/s10434-021-10552-7
PMID:34471985
Abstract
摘要

相似文献

1
Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS).
Ann Surg Oncol. 2022 Mar;29(3):1528-1529. doi: 10.1245/s10434-021-10552-7. Epub 2021 Sep 2.
2
Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast.与乳腺导管内癌（原位导管癌）治疗相关的病理生物学考量
CA Cancer J Clin. 1997 Jan-Feb;47(1):52-64. doi: 10.3322/canjclin.47.1.52.
3
Adjuvant Radiation Therapy for Ductal Carcinoma In Situ of the Breast: A Clinician's Dilemma.乳腺癌导管原位癌的辅助放疗：临床医生的困境
Ann Surg Oncol. 2023 Oct;30(11):6281-6283. doi: 10.1245/s10434-023-13691-1. Epub 2023 Jun 6.
4
Survival benefit of breast-conserving surgery with adjuvant radiotherapy for young women with ductal carcinoma in situ: A population-based cohort study.保乳手术联合辅助放疗对年轻导管原位癌女性的生存益处：一项基于人群的队列研究。
Asian J Surg. 2023 Aug;46(8):3173-3175. doi: 10.1016/j.asjsur.2023.02.107. Epub 2023 Mar 8.
5
No Treatment Versus Partial Mastectomy Plus Radiation for Ductal Carcinoma In Situ.导管原位癌的无治疗与保乳手术加放疗对比
Ann Surg Oncol. 2022 Jan;29(1):39-41. doi: 10.1245/s10434-021-10758-9. Epub 2021 Sep 1.
6
What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?分子诊断能为导管原位癌的局部区域治疗建议增添什么？
J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw270.
7
Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
Lancet. 2023 Jan 7;401(10370):23-24. doi: 10.1016/S0140-6736(22)02399-6.
8
Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
Lancet. 2023 Jan 7;401(10370):24. doi: 10.1016/S0140-6736(22)02373-X.
9
Breast radiotherapy for ductal carcinoma in situ: could less be more?
Lancet. 2022 Aug 6;400(10350):408-410. doi: 10.1016/S0140-6736(22)01381-2.
10
The problem of ductal carcinoma in situ of the breast.乳腺导管原位癌问题
Ann Chir Gynaecol. 1992;81(4):334-6.